John Chaw Chian Wang

John Chaw Chian Wang

Auto-generated profile, based on publicly available information

John Chaw Chian Wang

Department of Vascular Surgery, Singapore General Hospital, Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2021 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
PDF file
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
IBIan Patrick Barry
Ian Patrick Barry
MBMarianne Brodmann
Marianne Brodmann
TZThomas Zeller
Thomas Zeller
RVRamon Lee Varcoe
Ramon Lee Varcoe
GTGunnar Tepe
Gunnar Tepe


30 October 2026 in Journal of Endovascular Therapy
Verified
Journal Article
Open access
JDJames Evan Dodd
James Evan Dodd
MBMarianne Brodmann
Marianne Brodmann
JWJohn Chaw Chian Wang
John Chaw Chian Wang
GNGiovanni Nano
Giovanni Nano
TZThomas Zeller
Thomas Zeller
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
Background: Chronic limb-threatening ischaemia (CLTI) carries a high risk of death, limb loss, and impaired functional recovery despite revascularisation. Drug-coated balloons may reduce restenosis and repeat intervention after infrainguinal endovascular therapy, but long-term safety and effectiveness data in patients with CLTI remain limited. Methods: We performed a prespecified subgroup analysis of BIOLUX P-III, a prospective international post-market all-comers registry evaluating the Passeo-18 Lux paclitaxel-coated balloon for infrainguinal peripheral artery disease. Outcomes were compared between patients with and without CLTI through 60 months. Endpoints included freedom from major adverse events, clinically driven target-lesion revascularisation, major target-limb amputation, amputation-free survival and all-cause mortality. Time-to-event outcomes were analysed using Kaplan-Meier methods. Because follow-up completeness declined substantially by 60 months, late estimates were interpreted in the context of censoring, attrition and competing mortality. Results: Among 877 treated patients, 328 (37.4%) had CLTI. Technical success exceeded 98% in both groups. Patients with CLTI had greater baseline comorbidity, more advanced limb threat and more frequent below-the-knee disease. At 60 months, freedom from clinically driven target-lesion revascularisation was 85.3% in patients with CLTI and 78.3% in those without CLTI ( P = .59), and freedom from major adverse events was similar (76.5% vs 74.3%; P = .13). In contrast, 5-year survival was substantially lower in patients with CLTI (47.9% vs 76.7%; P < .001). Freedom from major target-limb amputation was lower (93.3% vs 99.3%; P < .001), and amputation-free survival was reduced (47.1% vs 75.7%; P < .001). Patients with CLTI received a lower cumulative paclitaxel dose despite higher mortality. Conclusions: Passeo-18 Lux treatment was associated with preserved lesion-level durability through 5 years, but CLTI identified a high-risk prognostic phenotype with poor survival and limb outcomes. These findings suggest that long-term outcomes in CLTI are influenced by systemic comorbidity, early limb vulnerability, competing mortality and wound-related factors beyond lesion-level device performance alone. Clinical Impact: This study provides clinically relevant insights into the long-term outcomes of patients with chronic limb-threatening ischaemia (CLTI) undergoing endovascular revascularisation with drug-coated balloons. Despite high procedural success, patients with CLTI experience substantially greater long-term mortality and adverse limb outcomes than those with intermittent claudication. These findings highlight the importance of recognising CLTI as a high-risk clinical phenotype requiring comprehensive cardiovascular risk reduction, multidisciplinary management, and structured postprocedural surveillance. The study’s principal contribution is its evaluation of five-year outcomes in a real-world, all-comers population, providing valuable evidence to inform patient counselling, individualised treatment strategies, and long-term clinical decision-making.